The inaugural AACR Drug Discovery and Development (AACR D3) meeting will convene experts to reshape the future of oncology...
Cigarette smoking is the leading cause of death from lung cancer in the United States. That’s why November, Lung...
Last week, the U.S. Food and Drug Administration (FDA) approved the molecularly targeted therapeutic acalabrutinib (Calquence) for treating adults...
Several clinical trials are underway in which PARP inhibitors are being tested in breast cancers, mostly triple-negative breast cancers,...
Paul Northcott, PhD, inaugural recipient of the AACR NextGen Grant for Transformative Cancer Research, has dedicated his research career...
Beginning this Friday, Philadelphia will host the 2017 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. The conference,...
Last week, the U.S. Food and Drug Administration (FDA) approved the second of a revolutionary new type of immunotherapy...
Despite advances in treatment, nearly 1,800 children and adolescents in the U.S. die annually from cancer. In an article...
For the second consecutive year, the American Association for Cancer Research (AACR) has been designated the beneficiary of Party...
Cancer cells ingest copious amounts of the simple sugar glucose. This addiction may hold the key to how cancer...
In recent years, the U.S. Food and Drug Administration has approved immune checkpoint inhibitors, a class of immunotherapy, to...